Table 1.
SBRT for pulmonary oligometastatic disease (OMD)
| Author/year | Study design | Patients | Lesions | (% CRC*) | Dose/fraction (Gy/fr) | Prescription | Local control | Overall survival | Toxicity grade≧3 |
|---|---|---|---|---|---|---|---|---|---|
| Norihisa 2005, Japan [10] | Retrospective | 34 | 43 | 26.5% | 42–60 Gy/3 fr | Isocenter | 90% (2y) | 84.3% (2y) | 3% |
| Rusthoven 2009, USA[11] | Phase I/II | 38 | 63 | 23.7% | 48- 60 Gy/ 3fr | 80–90% isodose | 96% (2y) | 39% (2y) | 7.9% |
| Takeda 2011, Japan [12] | Retrospective | 34 | 44 | CRC: 15 pts | 50 Gy/ 5fr | 80% isodose | CRC 72% (2y) | N.A | 3% |
| Non-CRC: 19 pts | Non-CRC 94% (2y) | N.A | |||||||
| Widder 2013, Nertherlands [13] | Retrospective | 42 | N.A.** | 73.8% | 60 Gy/ 3fr | N.A | 94% (2y) | 62% (3y) | 2.4% |
| Comito 2014, Italy [14] | Retrospective | 41 | 60 | 100% | 48–75 Gy/3-4fr | PTV D95％ | 70% (3y) | 58% (3y) | 0% |
| Jung 2015, Korea [15] | Retrospective | 50 | 79 | 100% | 48 Gy/4 fr (median) | 85–90% isodose | 70.6% (3y) | 64% (3y) | 0% |
| Rieber 2016, Germany [16] | Retrospective | 700 | N.A | 21.9% | 3–33 Gy × 1-13fr | 88.7% isodose (median) | 81.2% (2y) | 54.4% (2y) | 6.5% |
| Agolli 2016, Germany [17] | Retrospective | 44 | 69 | 100% | 23–45 Gy/1-3fr | 95% isodose | 60.2% (2y) | 50.8% (3y) | 0% |
| Jingu, 2017, Japan [18] | Retrospective | 93 | 104 | 100% | 40-65 Gy/3-15fr | Isocenter (83%) | 65% (3y) | 56% (3y) | 2% |
| Helou, 2017, UK [19] | Prospective cohort | 120 | 184 | CRC: 101 pts | 56-60 Gy/4fr | PTV D95% | 76.4% (2y) | N.A | 1.7% |
| Non-CRC: 83 pts | 48-52 Gy/4fr | PTV D95% | 91.7% (2y) | N.A | |||||
| Osti, 2018, Italy [20] | Retrospective | 129 | 166 | 31.7% | 30 Gy/1fr | 95% isodose | 80.1% (3y) | 34% (3y) | 7.4% |
| Sharma, 2018, Nertherland [21] | Retrospective | 206 | 327 | 57.3% | 30-60 Gy/1-8fr | 70–90% isodose | 85% (2y) | 36% (2y) | 2% |
| Berkovic, 2020, Belgium [22] | Retrospective | 104 | 132 | 33.7% | 20-60 Gy/3 or 5fr | 80% isodose | 77.8% (3y) | 72% (3y) | 2% |
| Yamamoto 2020, Japan [23] | Retrospective | 1378 | 1547 | 25.3% | 48 Gy/4fr | Isocenter (71.3%) | 81.3% (3y) | 72% (3y) | 2.5% |
| Siva 2021, Australia [24] | Randomized Phase II | 45 | 69 | 46.7% | 28 Gy/ 1fr | PTV D99% | 64% (3y) | 81% (3y) | 5% |
| 45 | 69 | 46.7% | 48 Gy/ 4fr | PTV D99% | 80% (3y) | 67% (3y) | 3% |
*CRC colorectal cancer, **NA not available, #Grade≧2, # PTV D95%/99%: the dose covering 95%/99% of the planning target volume (PTV)